Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma

JAMA. 2014 Dec 17;312(23):2505-7. doi: 10.1001/jama.2014.16095.

Authors

Jeremy S Abramson¹, Raymond T Chung²

Affiliations

¹ Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston2Harvard Medical School, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts3Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston.

PMID: 25514300
DOI: 10.1001/jama.2014.16095

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Antiviral Agents / therapeutic use*
Female
Guanine / analogs & derivatives*
Guanine / therapeutic use
Hepatitis B / prevention & control*
Hepatitis B Surface Antigens / blood*
Hepatitis B virus / immunology*
Humans
Lamivudine / therapeutic use*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male

Substances

Antiviral Agents
Hepatitis B Surface Antigens
Lamivudine
entecavir
Guanine